SynBio: unlocking the commercial potential of a new bioscience industryEuropean Pharmaceutical ReviewDespite its early stage, the volume of ongoing work to link breakthroughs in basic synthetic biology with promising applications underscores its consid… Continue reading
Breakthrough stem cell technology in type 1 diabetesDiabetes.co.ukA regenerative therapy company, known as Viacyte, just announced that a few patients have successfully been implanted with a pouch of stem cells they manufacture. The technology is calle… Continue reading
WeeklyHub |
Protea, Mass General Partner on Cancer Immunotherapy Tests
GenomeWeb Under the terms of the deal, Protea will work with MGH’s Vaccine and Immunotherapy Center to develop a diagnostic methodology for obtaining cancer cell molecular profiles, including the distribution of drugs within cancer cells and molecular response … Protea Announces Research Agreement with Mass General HospitalMarkets Insider |
|
ATCC® Answers World Health Organization’s Call To Arms In The Race Against Antimicrobial Resistance
PR Newswire (press release) The ATCC Center for Translational Microbiology is a center of excellence created by ATCC and ILSE to focus on key challenges in current translational microbiology, including antimicrobial resistance, synthetic biology, microbial bioinformatics, and the … |
|
Stem cell hype: Join the conversation
HealthNewsReview.org If it had, it likely would have been about medical tourism. There would’ve been outrage directed at “third world” countries who allow unregulated and unproven stem cell “therapies” to be offered to desperate patients. Well, that concern is now closer … |
Triangle Business Journal |
Pfizer to invest $100M in NC for gene therapy
Burlington Times News SANFORD — Biopharmaceutical giant Pfizer Inc. plans to invest $100 million in a North Carolina plant to focus on a process by which genetic material is introduced to counter defective or missing genes. The company confirmed Gov. Roy Cooper’s news on … Pfizer investing $100M in Sanford plant expansion, adding jobsTriangle Business Journal |
|
Kite Pharma Submits IND for BCMA-Targeting CAR-T Cancer Immunotherapy
Genetic Engineering & Biotechnology News (press release) Kite Pharma said today it has submitted to the FDA an Investigational New Drug (IND) application to launch a Phase I, first-in-human trial of a chimeric antigen receptor T-cell (CAR-T) therapy that targets B-cell maturation antigen (BCMA) in patients … |